Bieche We, Parfait B, Tozlu S, Lidereau R, Vidaud M: Quantitation from androgen receptor gene phrase inside sporadic nipple cancers by the real-go out RT-PCR: proof you to definitely MYC try a keen AR-regulated gene. Carcinogenesis. 2001, twenty-two (9): 1521-1526. /carcin/twenty-two.nine.1521.
Bratthauer GL, Lininger RA, Boy YG, Tavassoli FA: Androgen and you will the hormone estrogen receptor mRNA status from inside the apocrine carcinomas. Diagn Mol Pathol. 2002, 11 (2): 113-118. 9606-200206000-00008.
Gatalica Z: Immunohistochemical studies of apocrine nipple lesions. Consistent over-expression off androgen receptor followed closely by losing estrogen and progesterone receptors during the apocrine metaplasia and you may apocrine carcinoma inside situ. Pathol Res Pract. 1997, 193 (11-12): 753-758.
Am J Clin Pathol
Soreide JA, Lea OA, Varhaug JE, Skarstein An excellent, Kvinnsland S: Androgen receptors when you look at the operable breast cancer: regards to almost every other steroid hormonal receptors, correlations to prognostic facts and you can predictive really worth to possess effectation of additive tamoxifen treatment. Eur J Surg Oncol. https://datingranking.net/tr/meetmindful-inceleme/ 1992, 18 (2): 112-118.
Bayer-Gather IB, Smoller B: Androgen receptors: good marker to improve sensitivity to own pinpointing breast cancer inside facial skin metastasis regarding unfamiliar pri, thirteen (2): 119-122. /modpathol.3880021.
Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM: Matrix metalloproteinases: biologic activity and you can health-related implications. J Clin Oncol. 2000, 18 (5): 1135-1149.
Pang ST, Flores-Morales A good, Skoog L, Chuan YC, Nordstedt Grams, Pousette A: Control out of matrix metalloproteinase thirteen term of the androgen in prostate cancers. Oncol Rep. 2004, 11 (6): 1187-1192.
Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH, Morgan FJ: Androgen receptors in breast cancer. Cancer. 1984, 54 (11): 2436-2440. -0142(19841201)<2436::AID-CNCR2820541121>3.0.
Schippinger W, Regitnig P, Dandachi Letter, Wernecke KD, Bauernhofer T, Samonigg H, Moinfar F: Evaluation of prognostic importance of androgen receptor term when you look at the metastatic breast cancer. Virchows Arc. 2006, 449 (1): 24-30. /s00428-006-0213-6.
Parker RL, Huntsman DG, Lesack DW, Cupples JB, Offer DR, Akbari Meters, Gilks CB: Analysis away from interlaboratory type on the immunohistochemical dedication out of the hormone estrogen receptor standing having fun with a cancer of the breast muscle microarray. 2002, 117 (5): 723-728. /PEF8-GL6F-YWMC-AG56.
Vizoso FJ, Gonzalez LO, Corte MD, Rodriguez JC, Vazquez J, Lamelas ML, , Garcia-Muniz JL: Study of matrix metalloproteinases as well as their inhibitors inside cancer of the breast. Br J Disease. 2007, 96 (6): 903-911. /sj.bjc.6603666.
Narita D, Raica M, Suciu C, Cimpean A great, Anghel Good: Immunohistochemical expression regarding androgen receptor and you may prostate-certain antigen during the cancer of the breast. Folia Histochem Cytobiol. 2006, 49 (3): 165-172.
Egeblad Yards, Werb Z: The newest features toward matrix metalloproteinases in cancer tumors evolution. Nat Rev Cancer. 2002, 2 (3): 161-174. /nrc745.
Turk V, Kos J, Turk B: Cysteine cathepsins (proteases)–with the chief stage from cancer?. Cancer Cell. 2004, 5 (5): 409-410. /S1535-6108(04)00117-5.
Manes S, Llorente Yards, Lacalle RA, Gomez-Mouton C, Kremer L, Mira E, Martinez Ac: Brand new matrix metalloproteinase-9 controls the new insulin-instance increases factor-brought about autocrine response inside the DU-145 carcinoma cells. J Biol Chem. 1999, 274 (11): 6935-6945. /jbc..
Noe V, Fingleton B, Jacobs K, Crawford HC, Vermeulen S, Steelant W, Bruyneel Elizabeth, Matrisian LM, Mareel M: Release of an intrusion supporter Elizabeth-cadherin fragment by matrilysin and you may stromelysin-step 1. J Cellphone Sci. 2001, 114 (Pt 1): 111-118.
Fingleton B, Vargo-Gogola T, Crawford HC, Matrisian LM: Matrilysin [MMP-7] term chooses to have muscle with just minimal sensitivity to help you apoptosis. Neoplasia. 2001, step three (6): 459-468. /sj.neo.7900190.
CO;2-H
Stetler-Stevenson WG: Matrix metalloproteinases from inside the angiogenesis: a moving target for therapeutic intervention. J Clin Purchase. 1999, 103 (9): 1237-1241. /JCI6870.
Cornelius La, Nehring LC, Harding Elizabeth, Bolanowski Yards, Welgus HG, Kobayashi DK, Pierce RA, Shapiro SD: Matrix metalloproteinases create angiostatin: outcomes toward neovascularization. J Immunol. 1998, 161 (12): 6845-6852.
Jiang Y, Goldberg ID, Shi YE: State-of-the-art positions off muscle inhibitors of metalloproteinases when you look at the disease. Oncogene. 2002, 21 (14): 2245-2252. /sj.onc.1205291.